Do not use IGIM without first talking to your doctor if you have
-
IgA deficiency;
-
previously had an allergic reaction to an immune globulin product;
-
a low level of platelets in the blood (thrombocytopenia); or
-
a bleeding or blood clotting disorder.
You may not be able to use IGIM, or you may require a dosage adjustment or special monitoring during treatment.
IGIM is in the FDA pregnancy category C. This means that it is not known whether it will be harmful to an unborn baby. Do not use IGIM without first talking to your doctor if you are pregnant or could become pregnant during treatment.
It is not known whether IGIM passes into breast milk. Do not use IGIM without first talking to your doctor if you are breast-feeding a baby.
IGIM will be administered as an intramuscular (into a muscle) injection by a healthcare provider in a hospital or clinic setting.
Your doctor may want you to have blood tests or other forms of monitoring during treatment with IGIM to monitor progress and side effects.
Your healthcare provider will store IGIM as directed by the manufacturer. If you are storing IGIM at home, your healthcare provider will give you storage instructions.
Contact your healthcare provider if a dose of IGIM is missed.
IGIM is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can cause disease. Although IGIM is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit disease. Discuss with your doctor the risks and benefits of using IGIM.
Notify your doctor immediately if you experience a rare but serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives) to IGIM.
Other less serious side effects may also occur. Upon injection of the medication, some patients experience pain, tenderness, or irritation at the injection site.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
IGIM is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can cause disease. Although IGIM is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit disease. Discuss with your doctor the risks and benefits of using IGIM.
Do not receive vaccines that use live strains of the virus (e.g., measles, mumps, and rubella or MMR) during and for three months following treatment with IGIM. These vaccines may not work properly when IGIM has been recently administered.
Do not receive vaccines that use live strains of the virus (e.g., measles, mumps, and rubella or MMR) during and for three months following treatment with IGIM. These vaccines may not work properly when IGIM has been recently administered.
It is not known whether other medications will interact with IGIM. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines, including herbal products during treatment with IGIM.
Seek emergency medical attention or contact your healthcare provider if an overdose of IGIM is suspected.
No information is available regarding symptoms of an overdose of IGIM.